HC Wainwright Expects Higher Earnings for Maze Therapeutics

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Maze Therapeutics in a research note issued to investors on Monday, October 5th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.70) per share for the quarter, up from their prior forecast of ($0.77). HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.63) EPS, Q1 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.64) EPS, FY2027 earnings at ($2.60) EPS, FY2028 earnings at ($2.23) EPS, FY2029 earnings at ($2.05) EPS and FY2030 earnings at ($2.16) EPS.

Several other research analysts have also recently commented on the stock. Wedbush restated an “outperform” rating and issued a $48.00 target price on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Citigroup assumed coverage on Maze Therapeutics in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price on the stock. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $63.40.

Maze Therapeutics Stock Down 0.7%

MAZE stock opened at $26.25 on Wednesday. The stock has a market cap of $1.46 billion, a PE ratio of -10.42 and a beta of 2.16. The firm’s 50-day simple moving average is $26.88 and its 200 day simple moving average is $27.57. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76).

Insider Activity

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the sale, the chief marketing officer directly owned 16,142 shares in the company, valued at $445,680.62. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $27.58, for a total value of $206,850.00. Following the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $723,975. The trade was a 22.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 192,991 shares of company stock worth $5,152,084 over the last three months. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Maze Therapeutics during the second quarter valued at about $48,000. Royal Bank of Canada raised its position in Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after acquiring an additional 1,383 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Maze Therapeutics in the 2nd quarter valued at about $80,000. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the 4th quarter valued at about $145,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Maze Therapeutics during the 2nd quarter valued at about $200,000.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple EPS forecasts. The firm improved its estimates for Q3 2026 to a loss of $0.70 per share from $0.77, Q4 2026 to a loss of $0.71 from $0.80, FY2026 to a loss of $2.63 from $2.81, FY2027 to a loss of $2.60 from $3.27, FY2028 to a loss of $2.23 from $2.89, and FY2029 to a loss of $2.05 from $2.46. Although Maze is still expected to report losses, the revisions suggest expectations for narrower losses and may support investor sentiment. MAZE Stock Gets Increased EPS Forecast from HC Wainwright
• Positive Sentiment: The analyst maintained a Buy rating and $110 price target. HC Wainwright’s target implies substantial upside relative to Maze’s recent trading level, reflecting confidence in the company’s pipeline and longer-term commercial potential. Maze Therapeutics analyst coverage
• Neutral Sentiment: Maze will present clinical and preclinical kidney-disease data at ASN Kidney Week. An oral presentation will feature previously reported Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, while posters will discuss preclinical work supporting MZE782 and SLC6A19 inhibition. The October 21–25 event could provide additional visibility into the programs, though the announcement did not include new efficacy results. Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
• Negative Sentiment: HC Wainwright sharply reduced its FY2030 EPS forecast to a loss of $2.16 per share from a loss of $0.72. The downgrade contrasts with the nearer-term improvements and highlights uncertainty around Maze’s long-term path to profitability. The consensus forecast remains a loss of $2.72 per share for the current year.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.